Pharmacokinetic analysis of topotecan after superselective ophthalmic artery infusion and periocular administration in a porcine model

Retina

Volumn 32, Issue 2, 2012, Pages 387-395

  Schaiquevich, Paula ^a   Buitrago, Emiliano ^b   Ceciliano, Alejandro ^a   Fandino, Adriana C ^a   Asprea, Marcelo ^a   Sierre, Sergio ^a   Abramson, David H ^c   Bramuglia, Guillermo F ^b   Chantada, Guillermo L ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

ophthalmic artery infusion; pharmacokinetics; porcine model; retinoblastoma; topotecan

Indexed keywords

TOPOTECAN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTERY CATHETERIZATION; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; NONHUMAN; OPHTHALMIC ARTERY; SWINE; VITREOUS BODY;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CATHETERIZATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; INFUSIONS, INTRA-ARTERIAL; INJECTIONS, INTRAOCULAR; OPHTHALMIC ARTERY; SUS SCROFA; TOPOISOMERASE I INHIBITORS; TOPOTECAN; VITREOUS BODY;

EID: 84856591867     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31821e9f8a     Document Type: Article

References (34)

1. Abramson DH, Schefler AC. Update on retinoblastoma. Retina 2004;24:828-848. (Pubitemid 39657479)
2. Shields CL, Honavar SG, Shields JA et al. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 2002;120:460-464. (Pubitemid 34727817)
3. Gunduz K, Gunalp I, Yalcindag N, et al. Causes of chemo-reduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation. Ophthalmology 2004;111: 1917-1924. (Pubitemid 39311847)
4. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res 2009;26: 1197-1216.
5. Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev 2006; 58(11):1136-1163.
6. Wilson MW, Fraga CH, Fuller CE, et al. Immunohistochemical detection of multidrug-resistant protein expression in retino-blastoma treated by primary enucleation. Invest Ophthalmol Vis Sci 2006;47:1269-1273. (Pubitemid 46780730)
7. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology 2007;114:1378-1383. (Pubitemid 47008929)
8. Meadows AT, Chintagumpala M, Dunkel IJ, et al. Children's oncology group trials for retinoblastoma. In: Singh A, Damato B, Peter J, Murphree AL, Perry JD, eds. Essentials of Ophthalmic Oncology. Thorofare, NJ: SLACK Incorporated; 2009: 204-205.
9. Chantada GL, Fandino AC, Carcaboso AM, et al. A phase I study of periocular topotecan in children with intraocular retinoblastoma. Invest Ophthalmol Vis Sci 2009;50:1492-1496.
10. Pontes de Carvalho RA, Krausse ML, Murphree AL, et al. Delivery from episcleral exoplants. Invest Ophthalmol Vis Sci 2006;47:4532-4539. (Pubitemid 46579382)
11. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 1999;106:1947-1950.
12. Kaneko A, Suzuki S. Eye-preservation treatment of retinoblas-toma with vitreous seeding. Jpn J Clin Oncol 2003;33:601-607. (Pubitemid 43102812)
13. Chevez-Barrios P, Chintagumpala M, Mieler W, et al. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol 2005;23:7927-7935. (Pubitemid 46657392)
14. Abramson DH, Dunkel IJ, Brodie SE, et al. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 2008;115:1398-1404, 1404.e1391.
15. Abramson DH, Dunkel IJ, Brodie SE, et al. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology 2010;117: 1623-1629.
16. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retino-blastoma. Int J Clin Oncol 2004;9:69-73. (Pubitemid 38619319)
17. Shields CL, Ramasubramanian A, Rosenwasser R, Shields JA. Superselective catheterization of the ophthalmic artery for intraarterial chemotherapy for retinoblastoma. Retina 2009;29: 1207-1209.
18. Balmer A, Munier F, Zografos L. New strategies in pediatric ophthalmic oncology [in French]. Rev Med Suisse 16 2008;4: 139-143. (Pubitemid 351300017)
19. Dondelinger RF, Ghysels MP, Brisbois D, et al. Relevant radiological anatomy of the pig as a training model in interventional radiology. Eur Radiol 1998;8:1254-1273. (Pubitemid 128662787)
20. Moren H, Undren P, Gesslein B, et al. The porcine retinal vasculature accessed using an endovascular approach: a new experimental model for retinal ischemia. Invest Ophthalmol Vis Sci 2009;50:5504-5510.
21. Carcaboso AM, Bramuglia GF, Chantada GL, et al. Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy. Invest Ophthalmol Vis Sci 2007;48:3761-3767. (Pubitemid 351261115)
22. Carcaboso AM, Chiappetta DA, Opezzo JA, et al. Episcleral implants for topotecan delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci 2010;51:2126-2134.
23. Buitrago E, Hocht C, Chantada G, et al. Pharmacokinetic analysis of topotecan after intravitreal injection. Implications for retinoblastoma treatment. Exp Eye Res 2010;91: 9-14.
24. Laurie NA, Gray JK, Zhang J, et al. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res 2005;11:7569-7578. (Pubitemid 41507720)
25. Chantada GL, Fandino AC, Casak SJ, et al. Activity of topotecan in retinoblastoma. Ophthalmic Genet 2004;25: 37-43. (Pubitemid 38526527)
26. Hocht C, Opezzo JA, Taira CA. Microdialysis in drug discovery. Curr Drug Discov Technol 2004;1:269-285.
27. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource; 2006.
28. Shafiee A, McIntire GL, Sidebotham LC, Ward KW. Experimental determination and allometric prediction of vitreous volume, and retina and lens weights in Gottingen minipigs. Vet Ophthalmol 2008;11:193-196. (Pubitemid 351589466)
29. Ranta VP, Mannermaa E, Lummepuro K, et al. Barrier analysis of periocular drug delivery to the posterior segment. J Control Release 2010;148:42-48.
30. Santana VM, Zamboni WC, Kirstein MN, et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 2003;9:633-640. (Pubitemid 36182595)
31. Pitkanen L, Ranta VP, Moilanen H, Urtti A. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest Ophthalmol Vis Sci 2005;46: 641-646. (Pubitemid 40270347)
32. Wilson TW, Chan HS, Moselhy GM, et al. Penetration of chemotherapy into vitreous is increased by cryotherapy and cyclosporine in rabbits. Arch Ophthalmol 1996;114: 1390-1395. (Pubitemid 26398725)
33. Dias CS, Mitra AK. Posterior segment ocular pharmacokinet-ics using microdialysis in a conscious rabbit model. Invest Ophthalmol Vis Sci 2003;44:300-305. (Pubitemid 36134288)
34. Olsen TW, Sanderson S, Feng X, Hubbard WC. Porcine sclera: thickness and surface area. Invest Ophthalmol Vis Sci 2002;43: 2529-2532. (Pubitemid 34809437)